vs
礼来（LLY）与甲骨文（ORCL）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是甲骨文的1.2倍（$19.3B vs $16.1B），甲骨文净利率更高（38.2% vs 34.4%，领先3.8%），礼来同比增速更快（42.6% vs 14.2%），过去两年礼来的营收复合增速更高（48.3% vs 10.0%）
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
甲骨文公司是全球知名的企业软件公司，主打数据库软件、企业级应用软件、云基础设施与云服务等业务，为全球各行业的企业提供数字化转型、数据管理与业务运营的技术解决方案，在全球企业级科技领域占据重要地位。
LLY vs ORCL — 直观对比
营收规模更大
LLY
是对方的1.2倍
$16.1B
营收增速更快
LLY
高出28.3%
14.2%
净利率更高
ORCL
高出3.8%
34.4%
两年增速更快
LLY
近两年复合增速
10.0%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.3B | $16.1B |
| 净利润 | $6.6B | $6.1B |
| 毛利率 | 82.5% | — |
| 营业利润率 | 42.8% | 29.5% |
| 净利率 | 34.4% | 38.2% |
| 营收同比 | 42.6% | 14.2% |
| 净利润同比 | 50.5% | 94.7% |
| 每股收益（稀释后） | $7.39 | $2.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LLYORCL
| Q4 25 | $19.3B | $16.1B | ||
| Q3 25 | $17.6B | $14.9B | ||
| Q2 25 | $15.6B | $15.9B | ||
| Q1 25 | $12.7B | $14.1B | ||
| Q4 24 | $13.5B | $14.1B | ||
| Q3 24 | $11.4B | $13.3B | ||
| Q2 24 | $11.3B | $14.3B | ||
| Q1 24 | $8.8B | $13.3B |
净利润LLYORCL
| Q4 25 | $6.6B | $6.1B | ||
| Q3 25 | $5.6B | $2.9B | ||
| Q2 25 | $5.7B | $3.4B | ||
| Q1 25 | $2.8B | $2.9B | ||
| Q4 24 | $4.4B | $3.2B | ||
| Q3 24 | $970.3M | $2.9B | ||
| Q2 24 | $3.0B | $3.1B | ||
| Q1 24 | $2.2B | $2.4B |
毛利率LLYORCL
| Q4 25 | 82.5% | — | ||
| Q3 25 | 82.9% | — | ||
| Q2 25 | 84.3% | — | ||
| Q1 25 | 82.5% | — | ||
| Q4 24 | 82.2% | — | ||
| Q3 24 | 81.0% | — | ||
| Q2 24 | 80.8% | — | ||
| Q1 24 | 80.9% | — |
营业利润率LLYORCL
| Q4 25 | 42.8% | 29.5% | ||
| Q3 25 | 41.1% | 28.7% | ||
| Q2 25 | 43.6% | 32.1% | ||
| Q1 25 | 27.2% | 30.8% | ||
| Q4 24 | 37.2% | 30.0% | ||
| Q3 24 | 13.9% | 30.0% | ||
| Q2 24 | 31.1% | 32.8% | ||
| Q1 24 | 28.9% | 28.2% |
净利率LLYORCL
| Q4 25 | 34.4% | 38.2% | ||
| Q3 25 | 31.7% | 19.6% | ||
| Q2 25 | 36.4% | 21.5% | ||
| Q1 25 | 21.7% | 20.8% | ||
| Q4 24 | 32.6% | 22.4% | ||
| Q3 24 | 8.5% | 22.0% | ||
| Q2 24 | 26.3% | 22.0% | ||
| Q1 24 | 25.6% | 18.1% |
每股收益（稀释后）LLYORCL
| Q4 25 | $7.39 | $2.10 | ||
| Q3 25 | $6.21 | $1.01 | ||
| Q2 25 | $6.29 | $1.19 | ||
| Q1 25 | $3.06 | $1.02 | ||
| Q4 24 | $4.88 | $1.10 | ||
| Q3 24 | $1.07 | $1.03 | ||
| Q2 24 | $3.28 | $1.11 | ||
| Q1 24 | $2.48 | $0.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3B | $19.2B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.5B | $30.0B |
| 总资产 | $112.5B | $205.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LLYORCL
| Q4 25 | $7.3B | $19.2B | ||
| Q3 25 | $9.9B | $10.4B | ||
| Q2 25 | $3.5B | $10.8B | ||
| Q1 25 | $3.2B | $17.4B | ||
| Q4 24 | $3.4B | $10.9B | ||
| Q3 24 | $3.5B | $10.6B | ||
| Q2 24 | $3.4B | $10.5B | ||
| Q1 24 | $2.6B | $9.5B |
总债务LLYORCL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $29.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LLYORCL
| Q4 25 | $26.5B | $30.0B | ||
| Q3 25 | $23.8B | $24.2B | ||
| Q2 25 | $18.3B | $20.5B | ||
| Q1 25 | $15.8B | $16.7B | ||
| Q4 24 | $14.2B | $13.7B | ||
| Q3 24 | $14.2B | $10.8B | ||
| Q2 24 | $13.6B | $8.7B | ||
| Q1 24 | $12.8B | $5.6B |
总资产LLYORCL
| Q4 25 | $112.5B | $205.0B | ||
| Q3 25 | $114.9B | $180.4B | ||
| Q2 25 | $100.9B | $168.4B | ||
| Q1 25 | $89.4B | $161.4B | ||
| Q4 24 | $78.7B | $148.5B | ||
| Q3 24 | $75.6B | $144.2B | ||
| Q2 24 | $71.9B | $141.0B | ||
| Q1 24 | $63.9B | $137.1B |
负债/权益比LLYORCL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2B | $2.1B |
| 自由现金流经营现金流 - 资本支出 | — | $-10.0B |
| 自由现金流率自由现金流/营收 | — | -62.1% |
| 资本支出强度资本支出/营收 | — | 74.9% |
| 现金转化率经营现金流/净利润 | 0.49× | 0.34× |
| 过去12个月自由现金流最近4个季度 | — | $-13.2B |
8季度趋势，按日历期对齐
经营现金流LLYORCL
| Q4 25 | $3.2B | $2.1B | ||
| Q3 25 | $8.8B | $8.1B | ||
| Q2 25 | $3.1B | $6.2B | ||
| Q1 25 | $1.7B | $5.9B | ||
| Q4 24 | $2.5B | $1.3B | ||
| Q3 24 | $3.7B | $7.4B | ||
| Q2 24 | $1.5B | $6.1B | ||
| Q1 24 | $1.2B | $5.5B |
自由现金流LLYORCL
| Q4 25 | — | $-10.0B | ||
| Q3 25 | — | $-362.0M | ||
| Q2 25 | — | $-2.9B | ||
| Q1 25 | — | $71.0M | ||
| Q4 24 | — | $-2.7B | ||
| Q3 24 | — | $5.1B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | $3.8B |
自由现金流率LLYORCL
| Q4 25 | — | -62.1% | ||
| Q3 25 | — | -2.4% | ||
| Q2 25 | — | -18.4% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | -19.0% | ||
| Q3 24 | — | 38.5% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 28.6% |
资本支出强度LLYORCL
| Q4 25 | — | 74.9% | ||
| Q3 25 | — | 57.0% | ||
| Q2 25 | — | 57.1% | ||
| Q1 25 | — | 41.5% | ||
| Q4 24 | — | 28.2% | ||
| Q3 24 | — | 17.3% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | 12.6% |
现金转化率LLYORCL
| Q4 25 | 0.49× | 0.34× | ||
| Q3 25 | 1.58× | 2.78× | ||
| Q2 25 | 0.55× | 1.80× | ||
| Q1 25 | 0.60× | 2.02× | ||
| Q4 24 | 0.56× | 0.41× | ||
| Q3 24 | 3.83× | 2.54× | ||
| Q2 24 | 0.49× | 1.93× | ||
| Q1 24 | 0.52× | 2.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
ORCL
| Software Support | $4.9B | 31% |
| Cloud Infrastructure | $4.1B | 25% |
| Cloud Applications | $3.9B | 24% |
| Services Business | $1.4B | 9% |
| Software License | $939.0M | 6% |
| Hardware Business | $776.0M | 5% |
